RHYTHM BIOSCIENCES LIMITED - ASX Briefs

*Disclaimer

RHYTHM BIOSCIENCES LIMITED (ASX: RHY)

RHY: UK Strategic Partnership with LINK Medical Solutions

RHYTHM BIOSCIENCES LIMITED

Rhythm Biosciences Ltd partners with LINK Medical Solutions Ltd for UK market entry of ColoSTAT® for colorectal cancer screening.
Partnership aims at providing local clinical validation, stakeholder engagement, and overall market access in the private and public healthcare sectors.
LINK Medical Solutions offers extensive experience in launching innovative medical technologies in the UK and other countries.

2023-05-24 10:02:00

RHY: UK CA Mark granted for ColoSTAT

RHYTHM BIOSCIENCES LIMITED

Rhythm confirms UKCA Mark certification is complete for ColoSTAT®, allowing it to be marketed and sold within the United Kingdom.
The certification enables access to an addressable market of approximately 24 million people aged from 45 to 74.
Rhythm expects to make further advances on its market entry into the UK in CY'23.

2023-05-17 09:35:00

RHY: Executive Management Change

RHYTHM BIOSCIENCES LIMITED

Chief Executive Officer and Managing Director, Glenn Gilbert, resigns from Rhythm Biosciences effective 21 April 2023.
Executive Chairman, Otto Buttula, to take on additional executive duties in the interim.
Board expresses gratitude for Glenn's contributions since his appointment as CEO in late 2018 and wishes him well for the future.

2023-04-19 10:35:00

RHY: ColoSTAT abstracts accepted at 2023 ASCO Annual Meeting

RHYTHM BIOSCIENCES LIMITED

Both ColoSTAT® abstracts have been accepted for presentation at the 2023 ASCO Annual Meeting.
The abstracts detail clinical data and economics for ColoSTAT® adoption in the USA.
The event is expected to have an attendance of over 40,000 healthcare professionals.

2023-04-06 10:15:00

RHY: Update to TGA Submission

RHYTHM BIOSCIENCES LIMITED

Rhythm Biosciences Ltd (ASX: RHY) has decided to withdraw its current ColoSTAT® application for an Australian Register of Therapeutic Goods (ARTG) listing.
The new ColoSTAT® application is expected to be submitted in the current calendar year.
This withdrawal does not impede the Company’s proposed market entry activities into other CE Mark conforming territories and additional international markets, including the U.S.A.

2023-03-06 09:47:00

RHY: Rhythm Maintains ISO Certification

RHYTHM BIOSCIENCES LIMITED

Rhythm Biosciences Ltd successfully attained and retained ISO certification for ColoSTAT®, its simple blood test for the detection of colorectal cancer.
The ISO certification was conducted by the British Standards Institution (BSI).
The successful attainment and retention of certification is key to support regulatory compliance, operational readiness and global commercialisation.

2023-02-15 09:53:00